NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 851199-59-2
Drug Levels and Effects
Summary of Use during Lactation
Linaclotide is minimally absorbed from the gastrointestinal tract and the drug and its active metabolite is not measurable in plasma following administration of recommended doses. Linaclotide would not be expected to enter the breastmilk or cause any adverse effects in breastfed infants. Linaclotide appears to be acceptable in nursing mothers and no special precautions are required.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date. However, the manufacturer reports that following oral administration of 72 mcg, 145 mcg, or 290 mcg of linaclotide once daily for 3 days to breastfeeding mothers taking linaclotide therapeutically, the concentrations of linaclotide and its metabolite were below the limits of quantitation (<0.25 mcg/L and <1 mcg/L, respectively) in all breast milk samples collected over 24 hours. No further details were provided.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Irritable Bowel Syndrome) Lubiprostone, Plecanatide, Polyethylene Glycol, Psyllium, Tenapanor
Substance Identification
Substance Name
Linaclotide
CAS Registry Number
851199-59-2
Drug Class
Breast Feeding
Gastrointestinal Agents
Peptides
Guanylate Cyclase C Agonists
Laxatives
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Plecanatide[Drugs and Lactation Database (...]Review Plecanatide. Drugs and Lactation Database (LactMed). 2006
- Review Peginesatide[Drugs and Lactation Database (...]Review Peginesatide. Drugs and Lactation Database (LactMed). 2006
- Review Pramlintide[Drugs and Lactation Database (...]Review Pramlintide. Drugs and Lactation Database (LactMed). 2006
- Review Daptomycin[Drugs and Lactation Database (...]Review Daptomycin. Drugs and Lactation Database (LactMed). 2006
- Review Enfuvirtide[Drugs and Lactation Database (...]Review Enfuvirtide. Drugs and Lactation Database (LactMed). 2006
- Linaclotide - Drugs and Lactation Database (LactMed)Linaclotide - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...